MSD buys Themis as part of COVID-19 plans

Merck Sharp & Dohme (MSD) is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Merck & Co to buy $1bn stake in Seattle Genetics

16 September 2020 Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin.

Big Pharma

Merck KGaA wins injunction after MSD trademark suit

21 May 2020 The English High Court has finalised the terms of a trademark injunction against US pharmaceutical company Merck, Sharp and Dohme (MSD), in favour of German rival Merck KGaA.

Big Pharma

Sanofi under fire over priority US access to COVID-19 vaccine

15 May 2020 Sanofi is facing criticism after CEO Paul Hudson said the US was likely to have priority access on any COVID-19 vaccine produced by the French pharmaceutical company.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

MSD buys Themis as part of COVID-19 plans

More on this story

Editor's picks

Editor's picks

More features